Canopy Growth (CGC) Q2 2027 Earnings Call Transcript
Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.
How this was made

The 30-second read
Why it matters
Traders can update expectations for gross margin trajectory (VAC reimbursement reduction), segment mix (international cannabis growth), and forward operating leverage from cultivation yield and EU GMP certifications that enable broader European product categories.
Market read
Company-specific earnings disclosures and explicit cultivation yield targets can drive repricing of FY28 profitability expectations, despite reimbursement-related margin pressure.
What to watch
Storz & Bickel revenue is down 44% year over year, so consolidated momentum may remain sensitive to consumer spending and product-cycle execution in that segment.
Background
The transcript discusses Canopy Growth’s Q2 FY27 performance across its cannabis segment and Storz & Bickel, including cultivation improvements after acquiring MTL and the impact of the VAC reimbursement cap.
Ticker impact
Canopy’s Q2 FY27 call discloses revenue growth, gross margin drivers from the VAC reimbursement cap, and a Kincardine yield plan of 25% to 30%.
Likely mixed reaction, with upside bias from the Kincardine yield/quality ramp and international momentum, offset by continued gross margin headwinds from the VAC reimbursement reduction.
The article contains multiple company-specific operating datapoints (net revenue, segment growth, gross margin drivers, synergy run-rate, and explicit yield targets) that can change near-term expectations, but it also emphasizes a known reimbursement-driven margin drag.
Market effects
Signals ongoing normalization of Canadian medical economics post-reimbursement changes and continued shift toward international and product-category expansion via EU GMP.
Emphasizes Europe expansion path (Smiths Falls EU GMP) and UK medical market entry, which may influence regional cannabis supply and pricing expectations.
Highlights cross-border regulatory manufacturing readiness (EU GMP) as a gating factor for scaling medical cannabis categories beyond flower.
Counterpoint
The yield target (25% to 30%) is contingent on execution and timing, while the VAC reimbursement reduction is a direct, potentially persistent margin headwind.
Key entities
- companyCanopy Growth
Subject of the earnings call transcript, providing Q2 FY27 results, margin drivers, cultivation yield targets, and EU GMP certification updates.
- business_segmentStorz & Bickel
Vaporization segment discussed with revenue decline and margin improvement tied to cost efficiencies under new management.
- acquisitionMTL Cannabis
Acquisition referenced as a driver of cultivation expertise and brand momentum in Canada.


